Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis [Yahoo! Finance]
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Yahoo! Finance
AUSTIN, Texas, March 12, 2026 BUSINESS WIRE )--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the commercial launch of Zenith genomics, its next-generation whole genome sequencing assay designed to significantly improve the detection of rare diseases. Natera is presenting on Zenith's unique platform and performance at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, taking place this week in Baltimore, Maryland. Zenith genomics was built to address one of the most critical challenges in medicine: timely and accurate diagnosis of rare genetic conditions. Rare diseases affect an estimated 30 million Americans annually , many of whom experience prolonged diagnostic odysseys (4-7 years on average). The cumulative economic burden of rare diseases in the United States was nearly $997 billion in 2019, including $449 billion in direct medical costs and $548 billion in indirect and non-
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease DiagnosisBusiness Wire
- MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026PR Newswire
- Natera (NTRA) had its price target lowered by Morgan Stanley from $265.00 to $250.00. They now have an "overweight" rating on the stock.MarketBeat
- Natera Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]Yahoo! Finance
NTRA
Earnings
- 2/26/26 - Miss
NTRA
Sec Filings
- 3/12/26 - Form 144
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- NTRA's page on the SEC website